

MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895
Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,
W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

MPL/33/QTR-2/2021-2022

12th November, 2021

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESPCHAR-B

Scrip Code: 500274

Sub: Un-Audited Financial Results for the Quarter ended 30th September, 2021

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter ended 30th September, 2021.

M/s. B.S. Subudhi & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report


The Board meeting commenced at 11:00 A.M. and concluded at 11:45 A.M.

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at www.mescopharma.com

This is for your information and records.

Thanking You,

Yours Faithfully,
For **Mesco Pharmaceuticals Limited**


N S Parameswaran
Company Secretary cum Compliance Officer



Limited Review Report on Unaudited Quarterly Financial Results of MESCO PHARMACEUTICALS LIMITED under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


We have reviewed the accompanying statement of Standalone Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended September 30; 2021 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S Subudhi & Co.
Chartered Accountants
Firm Registration No. 316006E


M K Sahoo, FCA
Partner
M. No.: - 068452
UDIN: 21068452AAAABO1141

Date: 12th November, 2021
Place: Delhi/Bhubaneswar

MESCO PHARMACEUTICALS LIMITED		Regd Office : UPPER KESALTON TALLITAL NANTAL UR 263001
Website: www. MescoPharma.com., Tel: 011-41587085, Email: nsparameswaran@mescosteel.com		
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE YEAR AND QUARTER ENDED SEPTEMBER 30, 2021		
(Figures in Rs.)		

Part-I	Particulars	Quarter ended			Half Year Ended			Year ended	
		30.09.2021 (Un-Audited)	30.06.2021 (Un-Audited)	30.09.2020 (Un-Audited)	30.09.2021 (Un-Audited)	30.09.2020 (Un-Audited)	31.03.2021 (Audited)	31.03.2020 (Audited)	31.03.2021 (Audited)
I	Revenue From Operations	-	-	-	-	-	-	-	-
II	Other Income	-	-	-	-	-	-	-	-
III	Total Income (I + II)	-	-	-	-	-	-	-	-
IV	EXPENSES								
	Cost of materials consumed	-	-	-	-	-	-	-	-
	Purchase of Stock-in Trade	-	-	-	-	-	-	-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-	-	-	-
	Employee benefits expense	-	-	-	-	-	-	-	-
	Finance Cost	30	30	30	60	30	-	-	-
	Depreciation and amortisation expense	-	-	-	-	-	-	-	-
	Other Expenses	5,000	5,000	6,000	10,000	12,000	983,321	983,321	39,061
	Total Expenses (IV)	5,030	5,030	6,030	10,060	12,030	983,321	983,321	39,061
	Profit/(loss) before exceptional items and tax (I-IV)	(5,030)	(5,030)	(6,030)	(10,060)	(12,030)	(983,321)	(983,321)	(39,061)
V	Exceptional items	-	-	-	-	-	-	-	-
VI	Profit/(Loss) Before Tax (V-VI)	(5,030)	(5,030)	(6,030)	(10,060)	(12,030)	(983,321)	(983,321)	(39,061)
VIII	Tax Expense:								
	(1) Current Tax	-	-	-	-	-	-	-	-
IX	(2) Deferred Tax								
	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(5,030)	(5,030)	(6,030)	(10,060)	(12,030)	(983,321)	(983,321)	(39,061)
X	Profit/(Loss) from discontinued Operations	-	-	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax X(X+XI)	-	-	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	(5,030)	(5,030)	(6,030)	(10,060)	(12,030)	(983,321)	(983,321)	(39,061)
XIV	Other Comprehensive Income	-	-	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising	(5,030)	(5,030)	(6,030)	(10,060)	(12,030)	(983,321)	(983,321)	(39,061)
XVI	Earnings/(Loss) Per Equity Share (for continuing operation):								
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.05)	(0.05)	(0.00)
XVII	Earnings/(Loss) Per Equity Share (for discontinued operation):								
	Basic and Diluted (face value of Rs. 10 each)	-	-	-	-	-	-	-	-
XVIII	Earnings/(Loss) Per Equity Share (for discontinued and Continuing								
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.05)	(0.05)	(0.00)

Notes

- 1) The Company has adopted Indian Accounting Standards (IND AS) prescribed under the Companies Act, 2013 read with relevant rules thereunder, with effect from April 1, 2017 and accordingly these financial results have been prepared in accordance with the measurement and recognition principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules made thereunder
- 2) The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- 3) The above audited financial results for the quarter and year ended on September 30, 2021 have been reviewed by the Audit Committee and have been approved by the Board of Directors in its meeting held on 12.11.2021.
- 4) Previous year period figures have been rearranged and regrouped wherever necessary to make them comparable with current period figures.
- 5) There were no manufacturing activities in the Company during the period under consideration

For and on Behalf of Board of Directors of
Mesco Pharmaceuticals Limited

Date : 12.11.2021
Place : New Delhi

Dhruv Singh
Director & CEO
DIN 02983286

Mesco Pharmaceuticals Limited

Statement of Assets & Liabilities			
(Figures in Rs.)			
S.No	Particulars	As at 30.09.2021 (Un-Audited)	As at 31.03.2021 (Audited)
	ASSETS		
(1)	Non-Current Assets		
	(a) Property, Plant and Equipment	1,798,760	1,798,760
	(b) Capital work-in-progress	-	-
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible assets	-	-
	(f) Intangible assets under development	-	-
1	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	1	1
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified)	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
(2)	Current Assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	29,702	29,761
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	-	-
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets	-	-
	Total Assets	1,828,464	1,828,523
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	197,381,000	197,381,000
	(b) Other Equity	(307,562,467)	(307,553,360)
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	111,833,355	111,834,307
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (Net)	-	-
	(d) Other non-current liabilities	-	-
(2)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	176,576	166,576
	(iii) Other financial liabilities (other than those specified in item (c))	-	-
	(b) other current liabilities	-	-
	(c) Provisions	-	-
	(d) Current Tax Liabilities (Net)	-	-
	Total Equity and Liabilities	1,828,464	1,828,523

For and on Behalf of Board of Directors of
Mesco Pharmaceuticals Limited

Date : 12.11.2021
Place : New Delhi

Dhruv Singh
Director & CEO

Mesco Pharmaceuticals Limited			
Cash Flow Statement for the year ended 31st March, 2021			
(Figures in Rs.)			
	Particulars	For the period ended 30th Sept, 2021	For the year ended 31st March, 2021
A.	<u>Cash Flow from Operating Activities</u>		
	Net Profit (Loss) before Tax & extra ordinary Item	(10,060)	(39,061)
	Adjustments for:		
	Provision for Income tax reversal	-	-
	Revaluation of investments	-	-
	Operating profit before working capital changes	(10,060)	(39,061)
	Working Capital changes:		
	Trade receivables	-	-
	Short term loans and advances	-	-
	Short Term Provisions	-	-
	Trade payable	10,000	20,000
	Other current assets	-	952
	Cash generated from operations	10,000	20,952
	Direct Taxes Paid	-	-
	Net Cash from operating activities	(60)	(18,109)
B.	<u>Cash Flow from Investing Activities</u>		
	Change in Fixed Asset	-	-
	Loans & Advances	-	-
	Interest on deposits	-	-
	Net Cash from investing activities	-	-
C.	<u>Cash Flow from Financing Activities</u>		
	Proceeds from issue of Share Capital	-	-
	Payment to Borrowings	-	-
	Proceeds from Loans and advances	(952)	(346,752)
	Net cash from financing activities	(952)	(346,752)
	Net change in cash & cash equivalent (A+B+C)	(1,012)	(364,861)
	Cash & Cash equivalents opening balance	29,761	394,623
	Cash & Cash Equivalents at the End of the Year	28,749	29,762

Notes:

i) The above statement of cash flow has been prepared under the 'Indirect Method' as set out in IndAS 7 - 'Statement of Cash Flows'.

**For and on Behalf of Board of Directors
Mesco Pharmaceuticals Limited**

Date : 12.11.2021
Place : New Delhi

**Dhruv Singh
Director & CEO
DIN 02983286**